CDKN2B and breast cancer: In an association of the transcriptomic signature of CDKN2B-AS1 with clinicopathological features, the lower expression level (1.64 ± 1.85) was associated with poor pathological grade compared to well-differentiated and intermediately differentiated tumors (2.65 ± 1.60, P = 0.004) in breast cancer patients.